{"filing":{"accession_number":"0001937653-26-000051","cik":"0001937653","ticker":"ZYME","company_name":"Zymeworks Inc.","form":"8-K","filing_date":"2026-08-25","report_date":"2026-08-25","primary_document":"zyme-20260825.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1937653/000193765326000051/zyme-20260825.htm"},"events":[{"id":29386,"run_id":26904,"accession_number":"0001937653-26-000051","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Zymeworks' partner Jazz Pharmaceuticals received FDA approval for Ziihera (zanidatamab) in first-line HER2+ gastroesophageal adenocarcinoma, triggering a $250 million milestone payment to Zymeworks and maintaining eligibility for up to $1.3 billion in additional milestones plus tiered royalties.","company_name":"Zymeworks Inc.","ticker":"ZYME","filing_date":"2026-08-25","form":"8-K","submitted_at":null,"items":[{"id":31649,"accession_number":"0001937653-26-000051","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Zymeworks announced that its partner Jazz Pharmaceuticals received FDA approval for Ziihera (zanidatamab) in first-line HER2+ gastroesophageal adenocarcinoma, triggering a $250 million milestone payment and unlocking up to $1.3 billion in additional milestones plus royalties. While this is a regulatory milestone for a partnered asset, it is primarily an operational/commercial achievement—the approval of a marketed product in a new indication—rather than a financial event (debt, equity, dividend) or governance matter. The material value derives from the milestone payment and future royalty streams, but the core disclosure centers on the regulatory approval and its commercial implications for Zymeworks' diversified revenue strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-25T14:55:54.225093+00:00","company_name":"","ticker":null,"filing_date":""},{"id":31650,"accession_number":"0001937653-26-000051","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Zymeworks disclosed that its partner Jazz Pharmaceuticals received FDA approval for Ziihera (zanidatamab) in first-line HER2+ gastroesophageal adenocarcinoma, triggering a $250 million milestone payment to Zymeworks and maintaining eligibility for up to $1.3 billion in additional milestones plus tiered royalties. While this is a regulatory milestone for a partnered asset, it is fundamentally an operational/commercial achievement—the approval of a marketed product by a partner—rather than a discrete financial transaction (debt issuance), M\u0026A event, or earnings release. The milestone payment is a consequence of the regulatory approval, not the primary event being disclosed.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-25T14:55:54.225093+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":31649,"accession_number":"0001937653-26-000051","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Zymeworks announced that its partner Jazz Pharmaceuticals received FDA approval for Ziihera (zanidatamab) in first-line HER2+ gastroesophageal adenocarcinoma, triggering a $250 million milestone payment and unlocking up to $1.3 billion in additional milestones plus royalties. While this is a regulatory milestone for a partnered asset, it is primarily an operational/commercial achievement—the approval of a marketed product in a new indication—rather than a financial event (debt, equity, dividend) or governance matter. The material value derives from the milestone payment and future royalty streams, but the core disclosure centers on the regulatory approval and its commercial implications for Zymeworks' diversified revenue strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-25T14:55:54.225093+00:00","company_name":"Zymeworks Inc.","ticker":"ZYME","filing_date":"2026-08-25"},{"id":31650,"accession_number":"0001937653-26-000051","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Zymeworks disclosed that its partner Jazz Pharmaceuticals received FDA approval for Ziihera (zanidatamab) in first-line HER2+ gastroesophageal adenocarcinoma, triggering a $250 million milestone payment to Zymeworks and maintaining eligibility for up to $1.3 billion in additional milestones plus tiered royalties. While this is a regulatory milestone for a partnered asset, it is fundamentally an operational/commercial achievement—the approval of a marketed product by a partner—rather than a discrete financial transaction (debt issuance), M\u0026A event, or earnings release. The milestone payment is a consequence of the regulatory approval, not the primary event being disclosed.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-25T14:55:54.225093+00:00","company_name":"Zymeworks Inc.","ticker":"ZYME","filing_date":"2026-08-25"}]}